Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study

Tytuł:
Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study
Autorzy:
Sarah Bertoli
Pierre-Yves Dumas
Emilie Bérard
Laetitia Largeaud
Audrey Bidet
Eric Delabesse
Suzanne Tavitian
Noémie Gadaud
Thibaut Leguay
Harmony Leroy
Jean-Baptiste Rieu
Jean-Philippe Vial
François Vergez
Nicolas Lechevalier
Isabelle Luquet
Emilie Klein
Audrey Sarry
Anne-Charlotte De Grande
Christian Récher
Arnaud Pigneux
Temat:
acute myeloid leukemia
flt3-itd mutation
flt3-tkd mutation
primary induction failure
refractory
relapse
tyrosine kinase inhibitors
gilteritinib
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło:
Cancers, Vol 12, Iss 4, p 773 (2020)
Wydawca:
MDPI AG, 2020.
Rok publikacji:
2020
Kolekcja:
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Typ dokumentu:
article
Opis pliku:
electronic resource
Język:
English
ISSN:
2072-6694
Relacje:
https://www.mdpi.com/2072-6694/12/4/773; https://doaj.org/toc/2072-6694
DOI:
10.3390/cancers12040773
Dostęp URL:
https://doaj.org/article/0432c07aaaf441ce82c72c58d85291af  Link otwiera się w nowym oknie
Numer akcesji:
edsdoj.0432c07aaaf441ce82c72c58d85291af
Czasopismo naukowe
A recent phase 3 trial showed that the outcome of patients with relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) improved with gilteritinib, a single-agent second-generation FLT3 tyrosine kinase inhibitor (TKI), compared with standard of care. In this trial, the response rate with standard therapy was particularly low. We retrospectively assessed the characteristics and outcome of patients with R/R FLT3-mutated AML included in the Toulouse−Bordeaux DATAML registry. Among 347 patients who received FLT3 TKI-free intensive chemotherapy as first-line treatment, 174 patients were refractory (n = 48, 27.6%) or relapsed (n = 126, 72.4%). Salvage treatments consisted of intensive chemotherapy (n = 99, 56.9%), azacitidine or low-dose cytarabine (n = 9, 5.1%), other low-intensity treatments (n = 17, 9.8%), immediate allogeneic stem cell transplantation (n = 4, 2.3%) or best supportive care only (n = 45, 25.9%). Among the 114 patients who previously received FLT3 TKI-free intensive chemotherapy as first-line treatment (refractory, n = 32, 28.1%; relapsed, n = 82, 71.9%), the rate of CR (complete remission) or CRi (complete remission with incomplete hematologic recovery) after high- or low-intensity salvage treatment was 50.0%, with a bridge to transplant in 34.2% (n = 39) of cases. The median overall survival (OS) was 8.2 months (interquartile range, 3.0−32); 1-, 3- and 5-year OS rates were 36.0% (95%CI: 27−45), 24.7% (95%CI: 1−33) and 19.7% (95%CI: 1−28), respectively. In this real-word study, although response rate appeared higher than the controlled arm of the ADMIRAL trial, the outcome of patients with R/R FLT3-mutated AML remains very poor with standard salvage therapy.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies